Get the Stockscreener App
3.75
1.63%
0.06
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - Markets Insider
Insider Selling: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Sells 3,678 Shares of Stock - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CEO Sells $41,122.97 in Stock - MarketBeat
Amylyx Pharmaceuticals' co-CEO Justin Klee sells $41,103 in shares - MSN
Amylyx Pharmaceuticals Executives Cash In on Stock Sales - TipRanks
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation - Markets Insider
Research Analysts Set Expectations for AMLX FY2025 Earnings - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out - Markets Insider
Short Interest in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Rises By 23.6% - MarketBeat
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - Markets Insider
AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Amylyx Pharmaceuticals, Inc. Investors Can Join the Class Action Lawsuit! - ACCESS Newswire
2025-02-02 | Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:AMLX | Press Release - Stockhouse Publishing
JPMorgan Chase & Co. Purchases 83,048 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - MarketBeat
Leerink Partnrs Brokers Increase Earnings Estimates for AMLX - Defense World
Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - Markets Insider
2025-01-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation | NDAQ:AMLX | Press Release - Stockhouse Publishing
FDA lifts clinical hold on Amylyx ALS drug study - MSN
FDA clears Amylyx to resume ALS drug trial in North America - MSN
Fierce Biotech Names Amylyx Pharmaceuticals as One of Its “Fierce 15” Biotech Companies of 2020 - Marketscreener.com
Clinical hold lifted from Phase 1 trial of ALS therapy AMX0114 - ALS News Today
FDA lifts clinical hold on Amylyx’s Phase I ALS trial - MSN
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets - BioSpace
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Hennion & Walsh Asset Management Inc. - Defense World
Amylyx Says FDA Lifts Clinical Hold on ALS-Drug Trial - MarketWatch
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis - Business Wire
Barclays PLC Buys 40,319 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Brokerages Set Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Price Target at $7.33 - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - AccessWire
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock By Investing.com - Investing.com Nigeria
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - AccessWire
Amylyx Pharmaceuticals Prices of Public Offering of Common Stock - citybiz
Amylyx stock dips after pricing $60M stock offering - MSN
Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock - BioSpace
Amylyx Pharmaceuticals Announces Common Stock Offering to Fuel Commercialization Plans - StockTitan
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire
Amylyx Pharmaceuticals co-CEO Justin Klee sells $30,201 in stock By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - AccessWire
Justin B. Klee Sells 7,471 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock - MarketBeat
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells shares worth $30,232 By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals co-CEO Joshua Cohen sells shares worth $30,232 - Investing.com
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):